stockrowVericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
Follow VCEL
Alert me
Vericel Corporation (VCEL) Return on assets
Vericel Corporation's return on assets over the twelve months to 30 September 2026 was 6.86%, up 3.3 percentage points from fiscal 2025 (3.59%). Over the past ten years it has ranged from −47.2% (fiscal 2016) to 3.59% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 3.59% | 0.95 |
| FY2024 | 2.64% | 3.66 |
| FY2023 | −1.02% | 5.45 |
| FY2022 | −6.47% | (3.14) |
| FY2021 | −3.33% | (4.93) |
| FY2020 | 1.60% | 8.71 |
| FY2019 | −7.11% | 2.28 |
| FY2018 | −9.39% | 24.12 |
| FY2017 | −33.5% | 13.69 |
| FY2016 | −47.2% | (7.29) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 46.5% |
| ADMA ADMA Biologics Inc compare | 28.0% |
| VCEL Vericel Corporation | 6.86% |
| PVLA Palvella Therapeutics, Inc. compare | −37.7% |
| CLDX Celldex Therapeutics, Inc. compare | −40.8% |
| IMNM Immunome, Inc. compare | −59.0% |
| PHVS Pharvaris N.V. compare | −64.4% |
| VERA Vera Therapeutics, Inc. compare | −72.3% |
| BHVN Biohaven Ltd. compare | −161.3% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on VCEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement